文献速递淋巴瘤

瑞典U-CAN淋巴瘤生物样本库的覆盖度、代表性与有效性评估:与全国登记处的比较

Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers.
PubMed 文献 · Br J Haematol · 2024-09-03

该研究评估了瑞典U-CAN生物样本库淋巴瘤collection的覆盖度、代表性与有效性。2011-2019年U-CAN Uppsala地区淋巴瘤患者覆盖度为39%,2020-2021年疫情期间降至10%。纳入患者总生存优于全国患者(HR=0.70),但病因特异性生存与分期分布相似。

要点

  • U-CAN Uppsala地区2011-2019年淋巴瘤患者覆盖度为39%,2020-2021年降至10%。
  • 纳入患者总生存优于全国患者(HR=0.70,95%CI 0.60-0.82)。
  • 纳入患者体能状态更好、更年轻(OR=0.21)、合并症更少(OR=0.66)。

核心结论

  • U-CAN生物样本库选择性纳入更年轻、社会经济地位更高、体能状态更好的患者,但病因特异性生存与登记处相似,提示其可用于预后生物标志物研究。

研究设计与样本

  • 截至2022年,U-CAN Uppsala有889例淋巴瘤患者可用样本,U-CAN Umeå有329例。
  • 2011-2021年U-CAN Uppsala地区诊断患者(n=843)与瑞典淋巴瘤登记处链接,其中2019年前诊断亚组(n=727)与人群登记处链接。

主要发现

  • 2011-2019年U-CAN Uppsala地区淋巴瘤患者覆盖度为39%,2020-2021年疫情期间降至10%。
  • 纳入患者总生存优于瑞典所有淋巴瘤患者(HR=0.70,95%CI 0.60-0.82)。
  • 纳入患者体能状态更好、更年轻(OR=0.21,95%CI 0.13-0.34)、合并症更少(OR=0.66,95%CI 0.56-0.78)。
  • 病因特异性生存与分期分布与登记处相似。
  • 问卷数据较国家登记处捕获的合并症更少。

局限性

  • 生物样本库评估很重要,因为即使如U-CAN这样基于人群的生物样本库也会选择更年轻、社会经济地位更高、体能状态更好的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Validation of biobanks and large cancer cohorts is essential in ensuring high-quality research results. We examined the coverage, generalisability and validity of the lymphoma collection of the Uppsala-Umeå Comprehensive Cancer Consortium (U-CAN) biobank in Sweden, one of the largest cancer biobanks in Europe. Up until 2022, 889 lymphoma patients in U-CAN Uppsala had available samples, and 329 in U-CAN Umeå. Patients diagnosed in the U-CAN Uppsala area 2011-2021 (n = 843) were linked to the nationwide Swedish Lymphoma Register, and a subset diagnosed before 2019 (n = 727) to population-based registers. The coverage was 39% of all lymphoma patients between 2011 and 2019 diagnosed in the U-CAN Uppsala area, with a pandemic decline to 10% during 2020-2021. The patients included had superior overall survival (hazard ratio = 0.70 [95% confidence interval, CI: 0.60-0.82]) than all lymphoma patients in Sweden. They had better performance status, were younger (odds ratio [OR] = 0.21 [95% CI: 0.13-0.34]) and had less comorbidities (OR = 0.66 [95% CI: 0.56-0.78]). However, cause-specific survival and stage distribution were similar. The questionnaire data captured less comorbidities compared to the national registers. Evaluations of biobanks are important, as even population-based biobanks such as U-CAN select younger patients with higher socioeconomical status and better performance status. However, the similar cause-specific survival as in the registries suggests U-CANs usefulness for prognostic biomarker studies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Forsgren E, Ekberg S, Smedby KE, et al. Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers. Br J Haematol. 2024. PMID: 39228094. doi:10.1111/bjh.19732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。